De-Escalation and Discontinuation of Biologics in IBD: What to Consider
Although the definition of remission varies, the goal of IBD treatment is to achieve and sustain remission.
Colorectal Disorders
Clinical Remission Observed With Risankizumab in Crohn Disease Trials
Risankizumab is currently FDA-approved under the brand name Skyrizi for the treatment of moderate to severe plaque psoriasis.
Generic Version of Amitiza Now Available
The Company has begun shipping both the 8mcg and 24mcg capsules; the capsules are supplied in 60-count bottles.
FDA to Review AVT02, a High Concentration Biosimilar to Adalimumab
AVT02 is a proposed biosimilar to Humira® (adalimumab) with high concentration (100mg/mL) dosage forms.
FDA Grants Orphan Drug Status to Live Biotherapeutic for Pouchitis
The FDA has granted Orphan Drug designation to EXE-346 (ExeGi Pharma) for the prevention of disease relapse in pouchitis.
Clinically Meaningful Improvements With Ozanimod in UC Trial
The True North study included patients with moderate to severe ulcerative colitis who had an inadequate response to prior treatment.
Prevalence of Adverse Pregnancy Outcomes Assessed With Biologics for IBD
The study aimed to determine the prevalence of adverse pregnancy outcomes associated with biologic use in women with IBD.
Results Mixed for Etrolizumab in Ulcerative Colitis
Etrolizumab is an investigational humanized monoclonal anti-ß7 antibody designed to selectively inhibit α4β7 and αEβ7 integrins.
Ortikos Now Available for Mild to Moderate Crohn Disease
Ortikos, an anti-inflammatory corticosteroid, is approved as a once-daily treatment for mild to moderate active Crohn disease and for maintenance of clinical remission.
Efficacy of Cannabinoids in Treating IBD Examined
Significant improvements in both clinical symptoms (ie, abdominal pain, general well-being, nausea, diarrhea, and decreased appetite) as well as QoL scores were observed with cannabinoids.
